PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab

2016 ◽  
Vol 12 (2) ◽  
pp. 139-148 ◽  
Author(s):  
Chanukya Dahagam ◽  
Aditya Goud ◽  
Abdelhai Abdelqader ◽  
Aditya Hendrani ◽  
Matthew J Feinstein ◽  
...  
Keyword(s):  
High Risk ◽  
Ldl Cholesterol ◽  
Pcsk9 Inhibitors ◽  
High Risk Patients ◽  
Cholesterol Levels ◽  
Risk Patients

PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab

2016 ◽  
Vol 12 (2) ◽  
pp. 149-157 ◽  
Author(s):  
Chanukya Dahagam ◽  
Aditya Goud ◽  
Abdelhai Abdelqader ◽  
Aditya Hendrani ◽  
Matthew J Feinstein ◽  
...  
Keyword(s):  
High Risk ◽  
Ldl Cholesterol ◽  
Pcsk9 Inhibitors ◽  
High Risk Patients ◽  
Cholesterol Levels ◽  
Risk Patients

P5327Are we being able to meet current guidelines LDL-cholesterol goals in very high risk patients? How many of them could benefit of PSCK9 inhibition by the FOURIER/ODYSSEY and NICE criteria?

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
T El Andere ◽  
J A T Soto ◽  
I S Moreira ◽  
M N Wamser ◽  
H C Freitas ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
High Risk ◽  
Statin Therapy ◽  
Ldl Cholesterol ◽  
Target Range ◽  
Pcsk9 Inhibitors ◽  
High Risk Patients ◽  
Risk Patients ◽  
Pcsk9 Inhibition ◽  
Very High

Abstract Background/Introduction With increasing evidence of LDL-cholesterol (LDL-c) lowering and a subsequent reduction in cardiovascular events, guidelines of different parts of the world aim for lower LDL-c goals by risk stratification. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition has been able to reduce up to 60% LDL-c levels, with further reduction in cardiovascular outcomes. Purpose Our aim was to evaluate the proportion of very high risk patients in a tertiary cardiology center that met LDL-c goal of less than 50mg/dL proposed by the Brazilian Society of Cardiology (BSC) guidelines. Furthermore, we assessed the number of patients that were receiving adequate statin intensity therapy and could benefit from PCSK9 inhibition by the FOURIER/ODYSSEY and by the National Institute for Health and Care Excellence (NICE) criteria. Methods We screened 2180 consecutive patients from March, 2018 to February, 2019 for cardiovascular risk factors, cholesterol and glycemic levels, and current medical therapy at use. Patients were stratified by level of risk, and compliance to recommended statin therapy was evaluated. We then analyzed how many of the very high risk patients, that were in use of high intensity statin therapy, met the inclusion LDL-c levels of the FOURIER/ODYSSEY trials (≥70mg/dL) and the NICE recommendations (≥140mg/dL) for the introduction of PCSK9 inhibitors. Results Of the 2180 patients enrolled to our study, 1225 (56.2%) patients were at very high cardiovascular risk level. Of these patients, 136 (11.1%) met LDL-c BSC guideline levels. Using the LDL-c target of 70mg/dL, an additional 320 (26.1%) patients were below target range. When analyzing statin therapy at use, 913 (74,5%) were receiving adequate statin therapy. Of the very high risk patients in adequate statin treatment, 617 (65.9%) by the FOURIER/ODYSSEY criteria and 88 (9.4%) patients by the NICE criteria would benefit from PCSK9 inhibitors. Conclusions With lower LDL-c goals, achievement of optimal LDL-c levels is now a challenge for current clinical practice. Even though many patients are receiving adequate guideline-based statin therapy, difficulty remains in achieving optimal treatment, especially in the higher risk stratum. These patients would benefit from PCSK9 inhibition, being the NICE criteria, a more cost-effective strategy, still applicable in a substantial portion of our patients.

LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There?

Drugs ◽  
2013 ◽  
Vol 73 (4) ◽  
pp. 293-301 ◽  
Author(s):  
Joost Besseling ◽  
Julian van Capelleveen ◽  
John J. P. Kastelein ◽  
G. Kees Hovingh
Keyword(s):  
High Risk ◽  
Ldl Cholesterol ◽  
High Risk Patients ◽  
Risk Patients ◽  
Low Do
Sign in / Sign up

Export Citation Format

Share Document